Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$74.88 USD

74.88
686,225

+1.34 (1.82%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Compared to Estimates, Globus Medical (GMED) Q4 Earnings: A Look at Key Metrics

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 1.69% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings

Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.

Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?

Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.

Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics

Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.

Globus Medical (GMED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

3 Medtech Stocks Likely to Top Estimates This Earnings Season

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?

Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.

Encompass Health (EHC) to Post Q4 Earnings: What's in Store?

Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.

Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?

Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.

Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?

Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.

Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?

HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors continue to be optimistic about Globus Medical (GMED), backed by the NuVasive merger and its prominence in the musculoskeletal field.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.

Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down

Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.

Globus Medical (GMED) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Why Globus Medical (GMED) is Poised to Beat Earnings Estimates Again

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.